

Datasheet: C12CA

BATCH NUMBER 152740

Description:	BABY RABBIT COMPLEMENT
Name:	BABY RABBIT COMPLEMENT
Format:	Serum
Product Type:	Serum
Quantity:	2 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Functional Assays (1)	▪			
Immunoassay	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.

Product Form	Baby rabbit serum - lyophilised
Reconstitution	Reconstitute with 2ml ice cold distilled water
Preservative Stabilisers	None present
Product Information	Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity studies.
Instructions For Use	Use within one hour of reconstitution, keeping on ice throughout.

References	<ol style="list-style-type: none"> 1. Council of Europe. (1983) Essential aspects of tissue typing: Preparation, use, storage of reagents and standardisation of complement. European Health Committee, Strasbourg, ISBN 92-871.224-4. 2. Edited by J.G.Ray. (1979) NIAID Manual of tissue typing techniques. Publication No.
-------------------	---

NIH-80-545.

3. Anderson, L.D. Jr *et al.* (1999) Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. [Cancer Res. 59 \(7\): 1525-30.](#)
4. Mason, J.C. *et al.* (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. [Circ Res. 91 \(8\): 696-703.](#)
5. Lidington, E.A. *et al.* (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. [Blood. 96 \(8\): 2784-92.](#)
6. De clerq, L. *et al.* (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes *in vitro* and depresses the development of pig adipose tissue. [J Anim Sci. 75 \(7\): 1791-7.](#)
7. Hung, M.C. *et al.* (2011) The *Neisseria meningitidis* Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate. [Infect Immun. 79: 3784-91.](#)
8. Lee, S.J. *et al.* (2012) Identification of a common immune signature in murine and human systemic Salmonellosis. [Proc Natl Acad Sci U S A. 109 \(13\): 4998-5003.](#)
9. Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal *Salmonella* requires high levels of complement for cell-free antibody-dependent killing. [J Immunol Methods. 387 \(1-2\): 121-9.](#)
10. Li, S.H. *et al.* (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells. [Circulation. 109: 833-6.](#)
11. Hyams, C. *et al.* (2010) *Streptococcus pneumoniae* resistance to complement-mediated immunity is dependent on the capsular serotype. [Infect Immun. 78: 716-25.](#)
12. Newcombe, J. *et al.* (2004) Infection with an avirulent *phoP* mutant of *Neisseria meningitidis* confers broad cross-reactive immunity. [Infect Immun. 72: 338-44.](#)
13. Mason, J.C. *et al.* (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. [Am J Physiol Cell Physiol. 282: C578-87.](#)
14. Sancho, D. *et al.* (2006) CD69 targeting differentially affects the course of collagen-induced arthritis. [J Leukoc Biol. 80: 1233-41.](#)
15. Hung MC *et al.* (2013) The adhesin complex protein (ACP) of *Neisseria meningitidis* is a new adhesin with vaccine potential. [MBio. 4 \(2\): pii: e00041-13.](#)
16. Goh YS *et al.* (2016) Bactericidal Immunity to *Salmonella* in Africans and Mechanisms Causing Its Failure in HIV Infection. [PLoS Negl Trop Dis. 10 \(4\): e0004604.](#)
17. Sawant S *et al.* (2016) Establishment of 3D Co-Culture Models from Different Stages of Human Tongue Tumorigenesis: Utility in Understanding Neoplastic Progression. [PLoS One. 11 \(8\): e0160615.](#)
18. Humbert MV *et al.* (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of *Neisseria meningitidis*. [PLoS One. 11 \(8\): e0160403.](#)
19. Nganje, C.N. *et al.* (2019) PepN is a non-essential, cell wall-localized protein that contributes to neutrophil elastase-mediated killing of *Streptococcus pneumoniae*. [PLoS One. 14 \(2\): e0211632.](#)
20. Dierckx de Casterlé I *et al.* (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine

neuroblastoma-bearing allogeneic bone marrow chimeras. [Cancer Immunol Immunother. 67 \(4\): 589-603.](#)

21. Cuesta-Mateos, C. *et al.* (2020) CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia [Biomarker Research.8, 54.](#)

22. Valton, J. *et al.* (2018) A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies. [Sci Rep. 8 \(1\): 8972.](#)

Storage	<p>Prior to reconstitution store at +4°C. Following reconstitution store at +4°C for 1 hour or aliquot and store at -70°C for longer.</p> <p>This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use.</p>
Guarantee	Guaranteed until date of expiry. Please see product label.
Health And Safety Information	Material Safety Datasheet documentation #10288 available at: https://www.bio-rad-antibodies.com/SDS/C12CA 10288
Regulatory	For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M350330:190307'

Printed on 18 Jan 2024